A phase II study of S-1 in relapsed small cell lung cancer

S-1 is a new oral fluoropyrimidine derivative designed to enhance anticancer activity and reduce gastrointestinal toxicity. This phase II trial aimed to evaluate S-1 in patients with relapsed small cell lung cancer (SCLC). SCLC patients who had experienced treatment failure with ≥1 prior chemotherap...

Descrición completa

Gardado en:
Detalles Bibliográficos
Main Authors: KUDO, KEITA, OHYANAGI, FUMIYOSI, HORIIKE, ATSUSHI, MIYAUCHI, EISAKU, TAHANAKA, HISASHI, YANAGITANI, NORIKO, SAITO, RYOUTA, KABURAKI, KYOUHEI, SAKATANI, TOSHIO, HORAI, TAKESHI, NISHIO, MAKOTO
Formato: Artigo
Idioma:Inglês
Publicado: D.A. Spandidos 2013
Assuntos:
Articles
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC3915806/
https://ncbi.nlm.nih.gov/pubmed/24649158
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3892/mco.2013.67
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares